AgingResearch.NewsJoin free

Medinova

CompanySwitzerland

Medinova develops 2 assets, the furthest approved (estriol). Mostly small molecule and microbiome acting on ESR2 and ESR1; based in Switzerland.

2
Assets
Furthest stage
Approved
2
Trials
4
Signals

Pipeline

2

  • estriol

    Activates estrogen receptors to restore vaginal epithelium and relieve symptoms of vulvar and vaginal atrophy.

    Approved, Small molecule, ESR2, ESR1, vaginal atrophy (Phase 3), atrophic vaginitis (Phase 1)

  • Gynoflor

    Combines estriol-mediated vaginal epithelial restoration with lactobacilli to restore vaginal flora.

    Phase 1, Microbiome, atrophic vaginitis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms4
  • Trials2
  • Signals11
  • Integrity notices1
  • Similar companies6

Intelligence